CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Mifepristone and misoprostol

Mifepristone and misoprostol

Last Updated: January 18, 2016

Result type: Reports

Project Number: SR0473 -000

Product Line: Reimbursement Review

Generic Name: Mifepristone and misoprostol

Brand Name: Mifegymiso

Manufacturer: Celopharma Inc.

Therapeutic Area: Medical termination of pregnancy (gestational age up to 49 days)

Indications: Medical termination of pregnancy (gestational age up to 49 days)

Submission Type: Initial

Project Status: Withdrawn

Mifepristone and misoprostol

Files